[DOI] [PMC free article] [PubMed] [Google Scholar] 91.van Bommel E.J.M., Muskiet M.H.A., van Baar M.J.B., Tonneijck L., Smits M.M., Emanuel A.L., Bozovic A., Danser A.H.J., Geurts F., Hoorn E.J., et al
Further delving into the use of neuropsychiatric drugs in the cases included in this study, we found that 81 individuals with GLP-1RA-related SSIBs had a history of neuropsychiatric drug use
GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis
10.7759/cureus.38630 49 KnezevichE.CrnicT.KershawS.DrincicA
Yet the soaring enthusiasm for so-called glucagon-like peptide-1 receptor agonists, first approved in 2005 , overshadows an array of risks related to their off-label use